The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
Open accessAbstract
Significance: Small-cell lung cancer (SCLC) is an aggressive carcinoma with few effective treatment options beyond first-line chemotherapy. BH3 mimetics, such as ABT-263, promote apoptosis in SCLC cell lines, but early phase clinical trials demonstrated no significant clinical benefit. Here, we examine the sensitivity of a large panel of cancer cell lines, including SCLC, to ABT-263 and find that high Bcl2-interacting mediator of cell death (BIM) and low myeloid cell leukemia 1 (MCL-1) expression together predict sensitivity. SCLC cells relatively resistant to ABT-263 are sensitized by TORC1/2 inhibition via MCL-1 reduction. Combination of ABT-263 and TORC1/2 inhibition stabilizes or shrinks tumors in xenograft models, in autochthonous SCLC tumors in a genetically engineered mouse model, and in a patient-derived xenograft SCLC model. Collectively, these data support a compelling new therapeutic strategy for treating SCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There is a growing body of evidence suggesting that deficient apoptosis induction following targeted therapy treatments can lead to a lack of efficacy”
From Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Self-citationABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernandez‐Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,404
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271
Rudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z. D., Shames, D. S., Bergbower, E. A. S., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,076
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“ABT-263 was well tolerated in the clinic with a dose-limiting toxicity of thrombocytopenia (22), an on-target toxicity of BCL-XL inhibition (23).”
BackgroundRoberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 855
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 829
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
Cited by
Sorted by citations
Rudin, C. M., Brambilla, E. M., Finn, C. F., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,675
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
“The central role of BIM in promoting apoptosis in response to targeted therapies has also been demonstrated in other targeted therapy paradigms, including HER2-amplified breast cancers (115), ALK-positive NSCLCs (116), BRAF-mutant melanomas (106), BRAF-mutant colorectal cancers (117), and PIK3CA-mutant breast cancers…”
Self-citationPathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V. V., & Konopleva, M. Y. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 311
Origins, genetic landscape, and emerging therapies of small cell lung cancerPreprint
Semenova, E. A., Nagel, R., & Berns, A. J. M. (2015) · Genes & Development · doi:10.1101/gad.263145.115 · Cited by 247
“The same model has also been used to test the efficacy of anti-apoptotic inhibitors both as single agents and in a combination regimen (Faber et al. 2015).”
BackgroundMethodRegulation of Bim in Health and Disease
Sionov, R. V., Vlahopoulos, S., & Granot, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.5492 · Cited by 233
“Small-cell lung cancer (SCLC) with high Bim expression is among the most sensitive cells to ABT-263 treatment [584].”
BackgroundSenescent alveolar macrophages promote early-stage lung tumorigenesis
Prieto, L. I., Sturmlechner, I., Graves, S. I., Zhang, C., Goplen, N. P., Yi, E. S., Sun, J., Li, H., & Baker, D. J. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.006 · Cited by 212
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
Drapkin, B. J., George, J., Christensen, C. L., Mino-Kenudson, M. A., Dries, R., Sundaresan, T. K., Phat, S., Myers, D. T., Zhong, J., Igo, P., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0935 · Cited by 216
Self-citationHDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models
Nguyen, T. T. T., Zhang, Y., Shang, E., Shu, C., Torrini, C., Zhao, J., Bianchetti, E., Mela, A., Humala, N., Mahajan, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129049 · Cited by 202
Bunn, P. A., Minna, J. D., Augustyn, A., Gazdar, A. F., Ouadah, Y., Krasnow, M. A., Berns, A. J. M., Brambilla, E. M., Rekhtman, N., Massion, P. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.012 · Cited by 180
“This combination also suppressed growth of autochthonous Trp53/Rb1 double mutant GEMM SCLC tumors 67 .”
Self-citationTargeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Inoue‐Yamauchi, A., Jeng, P., Kim, K., Chen, H., Han, S., Ganesan, Y. T., Ishizawa, K., Jebiwott, S., Dong, Y., Pietanza, M. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms16078 · Cited by 180
Simpson, K., Stoney, R., Frese, K. K., Simms, N., Rowe, W., Pearce, S. P., Humphrey, S., Booth, L., Morgan, D., Dynowski, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0046-2 · Cited by 176
D’Aguanno, S., & Bufalo, D. D. (2020) · Cells · doi:10.3390/cells9051287 · Cited by 158
Identification of DHODH as a therapeutic target in small cell lung cancer
Li, L., Ng, S. R., Colón, C. I., Drapkin, B. J., Hsu, P. P., Li, Z., Nabel, C. S., Lewis, C. A., Romero, R., Mercer, K. L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7852 · Cited by 140
Self-citationVenetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Lochmann, T. L., Floros, K. V., Naseri, M., Powell, K. M., Cook, W., March, R. J., Stein, G. T., Greninger, P., Maves, Y. K., Saunders, L. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1606 · Cited by 134
“In addition, we have previously demonstrated that BCL-2, the founding prosurvival BCL-2 family member, is highly expressed in 65% of cases (5, 6), as is BIM, a proapoptotic BCL-2 family member, which sensitizes SCLC to targeted therapies (7), in particular BH3 mimetics (8).”
BackgroundSelf-citationShahbandi, A., Rao, S. G., Anderson, A. Y., Frey, W. D., Olayiwola, J. O., Ungerleider, N., & Jackson, J. G. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0564-6 · Cited by 135
Ham, J., Costa, C., Sano, R., Lochmann, T. L., Sennott, E. M., Patel, N. U., Dastur, A., Gomez‐Caraballo, M., Krytska, K., Hata, A. N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.002 · Cited by 135
“The implementation of patient-derived cell lines and patientderived xenografts (PDXs) in preclinical studies has been helpful to evaluate and improve cancer therapeutics (Crystal et al., 2014; Faber et al., 2015).”
BackgroundInfluentialSelf-citationLeverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M. Y., & Letai, A. G. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 126
How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient
Hansen, E., Woods, R. J., & Read, A. F. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001110 · Cited by 123
Soderquist, R. S., Crawford, L. A., Liu, E., Lu, M., Agarwal, A., Anderson, G. R., Lin, K., Winter, P. S., Çakır, M., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-05815-z · Cited by 122
Signal pathways and precision therapy of small-cell lung cancer
Yuan, M., Zhao, Y., Arkenau, H., Lao, T., Chu, L., & Xu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01013-y · Cited by 117
“Currently, several clinical studies investigate the role of other Bcl-2 inhibitors including, ABT-263.”
BackgroundWang, M., Han, J., Marcar, L., Black, J. C., Liu, Q., Li, X., Nagulapalli, K., Sequist, L. V. D., Mak, R. H., Benes, C. H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0808 · Cited by 111
“To reactivate BIM, we treated KRASmut cells with the BH3 mimetic ABT-263, which releases BIM from complexes with BCL-2 and BCL-xL (40).”
Self-citationSmall cell lung cancer: Novel treatments beyond immunotherapy
Meijer, J.-J., Leonetti, A., Airò, G., Tiseo, M., Rolfo, C. D., Giovannetti, E., & Vahabi, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.004 · Cited by 107
BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
Gibson, C. J., & Davids, M. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0364 · Cited by 97
“Recently, for example, it was found that certain SCLC cell lines can be sensitized to BCL-2 inhibition with ABT-263 by inhibition of TORC1/2, which leads to reduced MCL-1 protein levels (69).”
Cellular and molecular biology of small cell lung cancer: an overview.
Karachaliou, N., Pilotto, S., Lazzari, C., Bria, E., de Marinis, F., & Rosell, R. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.02 · Cited by 96
Kim, D. W., Wu, N., Kim, Y., Cheng, P. F., Basom, R., Kim, D., Dunn, C. T., Lee, A. Y., Kim, K., Lee, C. S., et al. (2016) · Genes & Development · doi:10.1101/gad.279307.116 · Cited by 96
“Similarly, in the Rb/p53 autochthonous mouse model, mTOR inhibition using the active site inhibitor AZD8055 lacked efficacy as monotherapy, although this treatment clearly enhanced the effects of a BCL2 inhibitor (Faber et al. 2015).”
MethodSong, K.-A., Niederst, M. J., Lochmann, T. L., Hata, A. N., Kitai, H., Ham, J., Floros, K. V., Hicks, M. A., Hu, H., Mulvey, H. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1577 · Cited by 95
“Western blotting Western blots were performed as described previously (25) using the Invitrogen Midi-gel Tris-BIS system.”
MethodSelf-citationBH3-only protein BIM: An emerging target in chemotherapy
Shukla, S., Saxena, S., Singh, B. K., & Kakkar, P. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.09.002 · Cited by 87
Dammert, M. A., Brägelmann, J., Olsen, R. R., Böhm, S., Monhasery, N., Whitney, C. P., Chalishazar, M. D., Tumbrink, H. L., Guthrie, M. R., Klein, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11371-x · Cited by 82
Arai, S., Jonas, O. H., Whitman, M. A., Corey, E., Balk, S. P., & Chen, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0549 · Cited by 72
“The BH3 mimetic drugs currently in the clinic (navitoclax and venetoclax, respectively, targeting BCL2/BCLXL or BCL2) have efficacy in hematologic malignancy, but have had limited singleagent efficacy in solid tumors (5, 8, 10, 11).”
BackgroundDorantes-Heredia, R., Ruiz-Morales, J. M., & Cano-García, F. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.07.10 · Cited by 73
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
Thummuri, D., Khan, S. U., Underwood, P. W., Zhang, P., Wiegand, J. S., Zhang, X., Budamagunta, V., Sobh, A., Tagmount, A., Loguinov, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0474 · Cited by 73
“Hence, to avoid these toxicities, alternative pharmacologic agents that could cause MCL-1 suppression selectively in tumor cells would be of great importance to develop highly effective combination therapies with a platelet-sparing BCL-XL–targeting agent such as DT2216 (23, 26).”
BackgroundSenescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG
Balakrishnan, I., Danis, E. P., Pierce, A. M., Madhavan, K. P. C., Wang, D., Dahl, N. A., Sanford, B. L., Birks, D. K., Davidson, N., Metselaar, D. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108286 · Cited by 75
“To test whether anti-BH3 agents would affect DIPG cells, we first sequentially treated SU-DIPG04 cells with PTC028 for 5 days, followed by treatment with ABT263, a well-characterized BH3 mimetic (Faber et al., 2015).”
MethodMahoney, C. E., Pirman, D. A., Chubukov, V., Sleger, T., Hayes, S., Fan, Z. P., Allen, E. L., Chen, Y., Huang, L., Liu, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07959-4 · Cited by 69
Yan, X., Li, P., Zhan, Y., Qi, M., Liu, J., An, Z., Yang, W., Xiao, H., Wu, H., Qi, Y., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.031 · Cited by 65
Song, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0304 · Cited by 67
“MCL-1 is functional in the response of EGFRi in EGFR-mutant NSCLCs MCL-1 is an experimentally proven drug target in several cancers (37–40) and is an important oncogene downstream of TORC1 (21, 25, 36, 41).”
BackgroundSelf-citationKarachaliou, N., Codony‐Servat, J., Teixidó, C., Pilotto, S., Drozdowskyj, A., Codony, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gervais, R., et al. (2015) · Scientific Reports · doi:10.1038/srep17499 · Cited by 65
To Prime, or Not to Prime: That Is the QuestionPreprint
Potter, D. S., & Letai, A. G. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030841 · Cited by 69
“…3-kinase) inhibitors appears to increase the potency of navitoclax in preclinical models in NSCLC (non– small cell lung cancer), pancreatic cancer, and SCLC (Tan et al. 2013; Faber et al. 2014, 2015; Potter et al. 2016), although the clinical impact of these findings remains to be determined.”
BackgroundArai, S., Varkaris, A. S., Nouri, M., Chen, S., Xie, L., & Balk, S. P. (2020) · eLife · doi:10.7554/elife.54954 · Cited by 71
Anderson, G. R., Wardell, S. E., Cakir, M., Crawford, L., Leeds, J. C., Nussbaum, D. P., Shankar, P. S., Soderquist, R. S., Stein, E. M., Tingley, J. P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0348 · Cited by 53
Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Williams, M. M., Lee, L., Hicks, D. J., Joly, M. M., Elion, D. L., Rahman, B., McKernan, C., Sanchez, V. M., Balko, J. M., Stricker, T. P., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0280-t · Cited by 55
Novel therapies in small cell lung cancer.
Mamdani, H. M., Induru, R. R., & Jalal, S. I. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.07.20 · Cited by 52
Novel Therapies for Small Cell Lung Cancer
Koczywas, M., & Amanam, I. U. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_8 · Cited by 51
Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl‐xL inhibition
Nguyen, T. T. T., Ishida, C. T., Shang, E., Shu, C., Torrini, C., Zhang, Y., Bianchetti, E., Sanchez‐Quintero, M. J., Kleiner, G., Quinzii, C. M., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910769 · Cited by 51
“Because Bcl-2 family members are central regulators of cell death in malignant tumors (Preuss et al, 2013; Souers et al, 2013; Chan et al, 2015; Faber et al, 2015; Hata et al, 2015; Johnson-Farley et al, 2015; Elgendy et al, 2016; KarpelMassler et al, 2017c), we hypothesized that LXR agonists have…”
BackgroundBcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
Yi, H., Qiu, M., Yuan, L., Luo, Q., Pan, W., Zhou, S., Zhang, L., Yan, X., & Yang, D. (2020) · Cancer Medicine · doi:10.1002/cam4.3090 · Cited by 50
Yu, X., Li, W., Xia, Z., Xie, L., Ma, X., Liang, Q., Liu, L., Wang, J., Zhou, X., Yang, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3442-y · Cited by 50
Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma
Karpel‐Massler, G., Ishida, C. T., Zhang, Y., Halatsch, M., Westhoff, M., & Siegelin, M. D. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1356286 · Cited by 49
Pétigny-Lechartier, C., Duboc, C., Jebahi, A., Louis, M.-H., Abeilard, E., Denoyelle, C., Gauduchon, P., Poulain, L., & Villedieu, M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0342 · Cited by 52
“In addition, the ratioof basal Bim toMcl1 mRNA expression was reported to predict ABT-263 sensitivity more effectively than the expression of each biomarker alone in a panel of more than 500 cancer cell lines (39).”
BackgroundKhan, S. U., Kellish, P. C., Connis, N., Thummuri, D., Wiegand, J. S., Zhang, P., Zhang, X., Budamagunta, V., Hua, N., Yang, Y., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-022-01296-8 · Cited by 47
“The effectiveness of the combination in the GEM model was encouraging because the tumors in this model have been shown to be highly resistant to cisplatin plus etoposide doublet chemotherapy [26].”
BackgroundInfluentialFGFR1 inhibition in lung squamous cell carcinoma: questions and controversies
Weeden, C. E., Solomon, B., & Asselin-Labat, M.-L. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.49 · Cited by 44
Huang, T., Ding, X., Xu, G., Chen, G., Cao, Y. Q., Peng, C., Shen, S., Lv, Y., Wang, L., & Zou, X. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1831-7 · Cited by 43
Targeted Therapy and Immune Therapy for Small Cell Lung Cancer
Gadgeel, S. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0568-3 · Cited by 43
Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression
Kohli, J. S., Chen, G., Fitsiou, E., Doepner, M., Brandenburg, S. M., Faller, W. J., Ridky, T. W., & Demaria, M. (2022) · Nature Communications · doi:10.1038/s41467-022-35657-9 · Cited by 45
“Although a similar mechanism has been observed in small-cell lung cancer cells 44 , to our knowledge this is the fi rst study demonstrating this occurs in senescent primary cells.”
JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
Wang, H., Hong, B., Li, X., Deng, K., Li, H., Lui, V. W. Y., & Lin, W. (2017) · Oncotarget · doi:10.18632/oncotarget.21146 · Cited by 42
“Previously, ABT-263 has been shown to block the binding of Bcl-2 to Bim, but does not block the binding of Mcl-1 to Bim [10].”
BackgroundResultInfluentialLi, H., Liu, L., Chang, H., Zou, Z., & Xing, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0169-2 · Cited by 43
Targeted drugs in small-cell lung cancer.
Santarpía, M., Daffinà, M. G., Karachaliou, N., González‐Cao, M., Lazzari, C., Altavilla, G., & Rosell, R. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.12 · Cited by 41
Lallo, A., Gulati, S., Schenk, M. W., Khandelwal, G., Berglund, U. W., Pateras, I. S., Chester, C., Pham, T. M., Kalderén, C., Frese, K. K., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14542 · Cited by 40
“Given the emerging body of evidence that this treatment combination is effective in SCLC (Gardner et al., 2014; Faber et al., 2015; Potter et al., 2016), we questioned whether CDX3 and CDX4 ex vivo cultures were also sensitive to this combination.”
BackgroundGebru, M. T., Atkinson, J. M., Young, M. M., Zhang, L., Tang, Z., Liu, Z., Lu, P., Dower, C. M., Chen, L., Annageldiyev, C., et al. (2020) · Blood · doi:10.1182/blood.2019003124 · Cited by 38
Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Zhang, S., Chen, Y., Tian, C., He, Y., Tian, Z., Wan, Y., & Liu, T. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200610174453 · Cited by 37
Khan, S., Cao, L., Wiegand, J., Zhang, P., Zajac-Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D. (2024) · Cells · doi:10.3390/cells13060528 · Cited by 34
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Heisey, D. A. R., Lochmann, T. L., Floros, K. V., Coon, C. M., Powell, K. M., Jacob, S., Calbert, M. L., Ghotra, M. S., Stein, G. T., Maves, Y. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0277 · Cited by 35
Self-citationNeutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Zoeller, J. J., Vagodny, A., Taneja, K. L., Tan, B. Y., O’Brien, N. A., Slamon, D. J., Sampath, D., Leverson, J. D., Bronson, R. T., Dillon, D. A. R., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0743 · Cited by 37
“Mol Cancer Ther; 18(6) June 2019 Molecular Cancer Therapeutics 1118”
BackgroundInfluentialInhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Potter, D. S., Galvin, M., Brown, S., Lallo, A., Hodgkinson, C. L., Blackhall, F. H., Morrow, C. J., & Dive, C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0885 · Cited by 35
“S4A), consistent with observations of Faber and colleagues in H1048 cells and in a PDX model using the TORC1/2 inhibitor AZD8055 (39).”
BackgroundResultInfluentialThe chemical biology of apoptosis: Revisited after 17 years
Yang, S., Mao, Y., Zhang, H., Xu, Y., An, J., & Huang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.019 · Cited by 35
Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics
Das, S., & Samaddar, S. (2025) · Cancers · doi:10.3390/cancers17020255 · Cited by 32
Lee, Y., Wang, L., Huang, C., Shi, Y., & Chang, L. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.019 · Cited by 31
Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy
Floros, K. V., Lochmann, T. L., Hu, B., Monterrubio, C., Hughes, M. T., Wells, J. D., Morales, C. B., Ghotra, M. S., Costa, C., Souers, A. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717820115 · Cited by 30
Self-citationLu, Y., Bian, D., Zhang, X., Zhang, H., & Zhu, Z. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11686 · Cited by 30
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope
Lehman, J. M., Gwin, M. E., & Massion, P. P. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0609-2 · Cited by 27
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
Mukherjee, N., Strosnider, A., Vagher, B., Lambert, K. A., Slaven, S., Robinson, W. A., Amato, C. M., Couts, K. L., Bemis, J. G. T., Turner, J. A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0932-z · Cited by 27
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 28
“This is consistent with prior studies showing that BIM protein turnover is affected by EGFR downstream signals (22, 37, 38).”
Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers
Fairlie, W. D., & Lee, E. F. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210750 · Cited by 28
Williams, M. M., Lee, L., Werfel, T. A., Joly, M. M., Hicks, D. J., Rahman, B., Elion, D. L., McKernan, C., Sanchez, V. M., Estrada, M. V., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0072-x · Cited by 26
Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers
Williams, M. M., Elion, D. L., Rahman, B., Hicks, D. J., Sanchez, V. M., & Cook, R. S. (2019) · Oncotarget · doi:10.18632/oncotarget.27070 · Cited by 27
Στρατικόπουλος, Η., Kiess, N., Szabolcs, M. J., Pegno, S., Cheung, K., Wu, X., Poulikakos, P. I., Cheung, P., Schmidt, H., & Parsons, R. E. (2018) · Oncogene · doi:10.1038/s41388-018-0436-4 · Cited by 25
Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells
Ludwig, L. M., Hawley, K. M., Banks, D. B., Thomas-Toth, A. T., Blazar, B. R., McNerney, M. E., Leverson, J. D., & LaBelle, J. L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04285-4 · Cited by 25
Potter, D. S., Du, R., Bohl, S., Chow, K.-H., Ligon, K. L., Bueno, R., & Letai, A. G. (2023) · Nature Communications · doi:10.1038/s41467-023-38552-z · Cited by 24
HLA susceptibility genes in rheumatoid factor positive juvenile rheumatoid arthritis.
Vehe, R. K., Begovich, A. B., & Nepom, B. S. (1990) · PubMed · Cited by 24
Dalton, K. M., Lochmann, T. L., Floros, K. V., Calbert, M. L., Kurupi, R., Stein, G. T., McClanaghan, J., Murchie, E., Egan, R. K., Greninger, P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009620118 · Cited by 24
“We have used this platform to generate targeted therapy strategies that are in the process of clinical trial testing (3, 25, 26), as well as epigenetic targeted therapy strategies (27).”
MethodSelf-citationBritt, E., Raman, S., Leek, K., Sheehy, C. H., Kim, S. W., & Harada, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219398 · Cited by 22
Self-citationBCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer
Lochmann, T. L., Bouck, Y. M., & Faber, A. C. (2018) · Oncoscience · doi:10.18632/oncoscience.455 · Cited by 22
Self-citationLian, B. S. X., Yek, A. E. H., Shuvas, H., Rahman, S. F. A., Muniandy, K., & Mohana‐Kumaran, N. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3302-0 · Cited by 20
Screening and Validation of Molecular Targeted Radiosensitizers
Willers, H., Pan, X., Borgeaud, N., Korovina, I., Koi, L., Egan, R. K., Greninger, P., Rosenkranz, A., Kung, J., Liss, A. S., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.07.1694 · Cited by 21
Self-citationDiscovery of Mcl-1 inhibitors from integrated high throughput and virtual screening
Mady, A. S. A., Liao, C., Bajwa, N., Kump, K. J., Abulwerdi, F. A., Lev, K. L., Miao, L., Grigsby, S. M., Perdih, A., Stuckey, J. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27899-9 · Cited by 19
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
Shang, E., Zhang, Y., Shu, C., Ishida, C. T., Bianchetti, E., Westhoff, M., Karpel‐Massler, G., & Siegelin, M. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-33784-2 · Cited by 19
Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
Zhang, Y., Ishida, C. T., Shu, C., Kleiner, G., Sanchez‐Quintero, M. J., Bianchetti, E., Quinzii, C. M., Westhoff, M., Karpel‐Massler, G., & Siegelin, M. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-25802-0 · Cited by 18
Ding, X., Zhang, Y., Huang, T., Xu, G., Peng, C., Chen, G., Kong, B., Frieß, H., Shen, S., Lv, Y., et al. (2019) · PubMed Central · Cited by 18
Wu, Z., Hu, Z., Han, X., Li, Z., Zhu, Q., Wang, Y., Zheng, Q., & Yan, J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.087 · Cited by 18
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Dastur, A., Choi, A., Costa, C., Yin, X., Williams, A. F., McClanaghan, J., Greenberg, M., Roderick, J. E., Patel, N. U., Boisvert, J. L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0867 · Cited by 17
“As noted previously (25, 27, 29), MCL-1 levels increase in almost all the lines treated with ABT-263 (Supplementary Fig.”
BackgroundSelf-citationChiou, J., Lee, Y., Huang, C., Shi, Y., Wang, L., & Chang, L. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114857 · Cited by 17
Li, Y., Deutzmann, A., Choi, P. S., Fan, A. C., & Felsher, D. W. (2016) · Oncotarget · doi:10.18632/oncotarget.8731 · Cited by 16
“In particular, activation of BIMmediated apoptosis pathway using BH3 mimetics may synergize with targeted therapeutics to induce sustained tumor regression [17, 37-41].”
Vera, M. B., Morris-Hanon, O., Nogueiras, G. I., Ripari, L. B., Esquivel, M. I., Perez-Castro, C., Romorini, L., Sevlever, G. E., Scassa, M. É., & Videla-Richardson, G. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-20910-4 · Cited by 16
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress
Varkaris, A. S., Wang, K., Nouri, M., Kozlova, N. V., Schmidt, D. R., Stavridi, A.-M., Arai, S., Ambrosio, N., Poluben, L., Jiménez‐Vacas, J. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60238-x · Cited by 13
Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
Hao, Z., & Veedu, J. S. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.09.003 · Cited by 13
Inoue‐Yamauchi, A., & Oda, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.139 · Cited by 13
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0301 · Cited by 12
“There is a growing body of evidence suggesting that deficient apoptosis induction following targeted therapy treatments can lead to a lack of efficacy (37, 38).”
BackgroundOhgino, K., Terai, H., Yasuda, H., Nukaga, S., Hamamoto, J., Tani, T., Kuroda, A., Arai, D., Ishioka, K., Masuzawa, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14569 · Cited by 11
Aregawi, L. G., Shokrolahi, M., Gebremeskel, T. G., & Csiki, Z. (2023) · Cureus · doi:10.7759/cureus.46061 · Cited by 15
“Ginger has also been studied for its effects as an anti-emetic agent on other digestive complaints, including nausea and vomiting [21-27].”
BackgroundMcCorkle, J. R., Ahn, R., Cao, C. D., Hill, K. S., Dietrich, C. S., & Kolesar, J. (2024) · Cancers · doi:10.3390/cancers16071321 · Cited by 10
Rashid, M. M., Oh, H., Lee, H., & Jung, B. H. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.06.059 · Cited by 10
Yi, F., & Zhang, X. (2019) · Medicine · doi:10.1097/md.0000000000017253 · Cited by 9
“ABT-737,([22,23]) ABT-263,([24]) and A-1210477([25]) either are the preclinical or clinical anti-cancer drugs, which are efficient against tumors.”
Background
Metadata
- Authors
- Faber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., Edelman, E. J., Ebi, H., Yeo, A. T., Hata, A. N., Song, Y., Patel, N. U., March, R. J., Tam, A. T., Milano, R. J., Boisvert, J. L., Hicks, M. A., Elmiligy, S., Malstrom, S. E., Rivera, M. N., Harada, H., Windle, B. E., Ramaswamy, S., Benes, C. H., Jacks, T., & Engelman, J. A.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital Cancer Center, Boston, MA 02129;
- Koch Institute for Integrative Cancer Research At MIT (US)
- Virginia Commonwealth University (US)
- Massachusetts General Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-03-03
- Volume
- 112
- Issue
- 11
- Pages
- E1288-96
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4371986
- OpenAlex
- W1981797550
- Cited by
- 127
- References
- 46
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 10 · 2022: 9 · 2021: 9 · 2020: 15 · 2019: 14 · 2018: 21 · 2017: 15 · 2016: 13 · 2015: 7
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- HHS | NIH | National Cancer Institute (2P50 CA09057, R01CA40594, R01CA137008-01, 1U54HG006097-1, P30-CA14051)
- U.S. Department of Defense (W81-XWH-13-1-0325)
- Burroughs Wellcome Fund (n/a)
- American Cancer Society (n/a)
- Uniting Against Lung Cancer (n/a)
- Lung Cancer Research Foundation (n/a)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- navitoclax, venetoclax, BH3 mimetics, small cell lung cancer, building information modeling, Mcl-1, Bcl-2, Bcl-xL, apoptosis, combination therapy, AZD8055, rapamycin, drug resistance, cancer cell line sensitivity, patient-derived xenografts, genetically engineered mouse models
- MeSH terms
- Bcl-2-Like Protein 11, Mechanistic Target of Rapamycin Complex 1, Mechanistic Target of Rapamycin Complex 2, Aniline Compounds, Animals, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Genetic Engineering, Humans, Lung Neoplasms, Membrane Proteins, Morpholines, Proto-Oncogene Proteins, Remission Induction, Sulfonamides, Apoptosis, Inhibitory Concentration 50, Xenograft Model Antitumor Assays, Cell Line, Tumor, Multiprotein Complexes, Apoptosis Regulatory Proteins, Mice, Small Cell Lung Carcinoma, TOR Serine-Threonine Kinases, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
